Structural
Impact of Short-Term Complications on Mortality and Quality of Life After Transcatheter Aortic Valve Replacement

https://doi.org/10.1016/j.jcin.2018.11.008Get rights and content
Under an Elsevier user license
open archive

Abstract

Objectives

The aim of this study was to examine the independent association of short-term complications of transcatheter aortic valve replacement (TAVR) with survival and quality of life at 1 year.

Background

Prior studies have examined the mortality and cost implications of various complications of TAVR. However, many of these complications may primarily affect patients’ quality of life after TAVR, which has not been previously studied.

Methods

Among patients at intermediate or high surgical risk who underwent TAVR as part of the PARTNER (Placement of Aortic Transcatheter Valve) 2 studies and survived 30 days, the association between complications within the 30 days after TAVR and mortality and quality of life at 1 year was examined. Quality of life was assessed using the Kansas City Cardiomyopathy Questionnaire and the Short-Form 12. Complications assessed included major and minor stroke, life-threatening and major bleeding, vascular injury, stage 3 acute kidney injury, new pacemaker implantation, and mild and moderate or severe paravalvular leak (PVL). Multivariable models that included all complications as well as baseline clinical factors were used to examine the independent association of each complication with outcomes.

Results

Among 3,763 TAVR patients, major stroke and stage 3 acute kidney injury were associated with markedly increased risk for 1-year mortality, with adjusted hazard ratios of 5.4 (95% confidence interval [CI]: 3.1 to 9.5) and 4.9 (95% CI: 2.7 to 8.8), respectively, as well as poorer quality of life among survivors (reductions in 1-year Kansas City Cardiomyopathy Questionnaire overall summary score of 15.1 points [95% CI: 24.8 to 5.3 points] and 14.7 points [95% CI: 25.6 to 3.8 points], respectively). Moderate or severe PVL, life-threatening bleeding, and major bleeding were each associated with a more modest increase in mortality and decrement in quality of life, whereas mild PVL was associated with a small decrease in quality of life. After adjusting for baseline characteristics and other complications, need for a new pacemaker, minor stroke, and vascular injury were not independently associated with poor outcomes.

Conclusions

Among patients undergoing TAVR, similar events are associated with increased mortality and impaired quality of life at 1 year. These results suggest that despite considerable progress, efforts to further reduce stroke, acute kidney injury, bleeding, and moderate or severe PVL are likely to yield important clinical benefits and remain key targets for device iteration and procedural improvement.

Key Words

complications
quality of life
transcatheter aortic valve replacement

Abbreviations and Acronyms

AKI
acute kidney injury
CI
confidence interval
HR
hazard ratio
KCCQ
Kansas City Cardiomyopathy Questionnaire
KCCQ-OS
Kansas City Cardiomyopathy Questionnaire overall summary score
MCS
mental component summary score
PCS
physical component summary score
PVL
paravalvular leak
SF-12
Medical Outcomes Study Short-Form 12
STS
Society of Thoracic Surgeons
TAVR
transcatheter aortic valve replacement

Cited by (0)

The PARTNER trial was sponsored by Edwards Lifesciences. The present study was self-funded, and the funding organization for the trial did not play a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. Dr. Arnold is supported by a Career Development Grant Award (K23 HL116799) from the National Heart, Lung, and Blood Institute. Dr. Baron has received consulting income from Edwards Lifesciences and St. Jude Medical. Dr. Kodali has received consulting income from Edwards Lifesciences and Medtronic; and is an advisory board member for Thubrikar Aortic Valve, Paieon Medical, and St. Jude Medical. Dr. Thourani has served as an adviser for Edwards Lifesciences, Abbott Vascular, Boston Scientific, and Gore Vascular. Drs. Mack and Leon have received travel reimbursements from Edwards Lifesciences for activities related to their positions on the executive committee of the PARTNER trial. Dr. Cohen has received research grant support from Edwards Lifesciences, Medtronic, Boston Scientific, and Abbott Vascular; and has received consulting fees from Medtronic and Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.